PMA induced a dose-dependent upregulation ofB7 staining. This staining identifies a molecule closely related to B7 because it was blocked by purified recombinant B7 immunoglobulin. U pregulation ofB7 staining was first observed 16 h after PMA treatment and persisted for at least 48 h; it was protein kinase C dependent and required de novo protein synthesis. Anti-B7 MoAbs reduced specifically the capacity of PMA-HNK to trigger proliferation of allogeneic peripheral blood mononuclear cells and T cells. The combination of anti-B7 and anti-ICAM-1 MoAbs further reduced this response. We conclude that PMA upregulates on HNK the expression of a B7-like molecule that contributes in concert with ICAM-1 to the capacity ofPMA-HNK to induce proliferation of allogeneic T cells.] Invest D ermatol1 00: 275 -281, 1993 cells via an MHC-independent mechanism that is mediated in part by PMA-induced intercellular adhesion molecule (ICAM)-l on HNK [12] . These studies demonstrated for the first time that "activated" HNK can directly trigger a proliferative response in T cells. Interaction between ICAM-l (on PMA-HNK) and lymphocyte function-associated antigen (CDllajCD18) (LFA)-t (on T cells) was necessary ~ut not suffi.cient for this effect, raising the possibility that other costlmulatory Signals delivered by PMA-HNK were also required for efficient T-cell activation.
Recent~y, t.he i.nteraction of the B7 Ag [on antigen-presenting cell (APC)] wIth Its hgand CD28 (on T cells) has been shown to deliver activation signals to T cells distinct from those transduced via the T-cell receptor [13] [14] [15] [16] [17] . B7 is also called BBt because it was initially identified by two different antibodies (i.e., B7 and BB 1) that recognize identical (or highly related) glycoproteins with a molecu-lar weight of 44 -54 kDa. B7 shows low constitutive expression on resting B cells and monocytes; however, it can be readily upregulated by stimulation with mitogen, cytokines, anti-immunoglobulins (Ig), or anti-class II antibodies or by Epstein -Barr virustransformation [18] [19] [20] [21] [22] . In addition, B7 is expressed on different B-celllines and B-cell neoplasms and on human T-celllymphotropic virus-l-infected T-cell lines [18] [19] [20] 23] . CD28 is a 44-kDa homodimeric glycoprotein expressed by the m~ority of T cells in human peripheral blood [15, [24] [25] [26] . Interaction ofB7 and CD28 has been shown to mediate heterotypic adhesion of T and B cells [27] and to augment several T-cell functions, such as proliferation, cytokine production, adhesion, and cytotoxicity [17,28 -37] . Defective signalling via the B7/CD28 pathway has been implicated in the development of T-cell tolerance [38] . Taken together, these studies indicate that interaction ofB7 with CD28 delivers essential costimulatory signals, resulting in effective induction and amplification of T -cell-mediated immune responses [13 -17] .
In the present study, we questioned whether B7-associated signals may contribute to the capacity ofPMA-HNK to induce T-cell proliferation. Indeed, PMA-HNK upregulate the expression of a surface molecule closely related to B7 on B cells and monocytes. This molecule, is functionally active because it contributes to the capability of PMA-HNK to activate resting allogeneic peripheral blood mononuclear cells (PBMe) or T cells. Furthermore, this B7 molecule and ICAM-l expressed simultaneously by PMA-HNK were found to cooperate in delivering activation signals to T cells. On the basis of these findings, we hypothesize that during T-cellmediated skin disease, B7 and ICAM-1 are co-expressed on "activated" epidermal and dermal cells and mediate adhesion and activation of T lymphocytes.
MATERIALS AND METHODS
Media and Chemicals Serum-free keratinocyte basal growth medium (KGM) was supplemented with recombinant epidermal growth factor, bovine pituitary extract, and 1 % penicillinstreptomycin (all from Gibco, Eggenstein, Germany). RPMI 1640 (Gibco) was supplemented with 10% heat-inactivated fetal bovine serum; 25 mM N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic ac id (Sigma Chemical Co., Munich, Germany); 1 mM non-essen-
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tial amino acids (Gibco); 2 mM L-glutamine (Gibco); 1 nM 2-mercaptoethanol (Sigma); and 1% penicillin -streptomycin (Gibco). Minimal essential medium (Gibco) was supplemented with 1.282 Dornase U/ml DNAse I (Boehringer, Ingelheim, Germany), 10% fetal bovine serum, and 1 % penicillin-streptomycin (Gibco During subsequent passages, HNK were harvested and reseeded identically. For the experiments outlined below, second-to fifthpassage HNK from 21 different donors were used.
Isolation of PBMC and T-Cell Purification PBMC were enriched from heparinized peripheral blood obtained from human volunteers by density centrifugation over 1.077 Histopaque (Sigma). Cells recovered from the interface were washed and resuspended in supplemented RPMI 1640. PBMC viability was greater than 90%, as determined by trypan blue exclusion. T cells were purified as previously described [42] . Briefly, PBMC were layered on glass petri dishes (1 h, 37°C), and non-adherent cells were treated with L-Leucine-O-methyl ester (0.45,ug/ml, 1 h, room temperature) to remove monocytes and finally passed over nylon wool columns (NEN Products, Boston, MA). The resulting CD3+ populations were more than 90% pure, as determined by f1uorescence-activated cell sorter (FACS) analysis and did not proliferate in response to 0.5 ,ug/ml concanavalin A.
Immunostaining and FACS Analysis Sixteen hours prior to staining, HNK were treated with PMA at the indicated concentrations or left untreated . HNK were harvested as described above, and viability, determined by trypan blue exclusion, ranged from 80% to 90%. Prior to staining with MoAb, HNK were pre-incubated with 0.1 % bovine serum albumin in phosphate-buffered saline (PBS) for 30 min at 37"C in 5% CO 2 to block non-specific antibody binding, washed twice, and then resuspended in PBS containing 0.1 % sodium azide. Cells were aliquoted at 3 -6 X 10 5 into polystyrene tubes, and all staining was performed for 20 min at 4 ° C using the indicated primary reagents. HNK labeled with irrelevant MoAb of the same isotype served as specificity controls. In some experiments, anti-B7 MoAbs were pre-incubated with purified B7-Ig or human IgG (lh, 4°C) prior to use. After two washes in PBS, HNK were counterstained with appropriate fluorescein isothiocyanate (FITC) -conjugated secondary antibodies [i.e., goat anti-mouse,uchain, F(ab')z fragments of goat anti-mouse IgG or goat anti-mouse IgG (heavy and light chain) (both from Dianova, Hamburg, Germany)]. Cells were analyzed by flow cytometry using an FACScan (Becton Dickinson, Sunnyvale, CA) equipped with the Consort 30 and FACScan research software. Propidium iodide (PI) (1 ,u/ml) was added to each sample to exclude dead cells.
Proliferation Assays HNK (second to fifth passages) were suspended in KGM and seeded into 96-well plates at 2 X 10 4 cells/ dish . After 3 -4 d, HNK were treated with 0 or 25 ng/ml PMA for 16 h at 37°C in 5% CO 2 • Initially, keratinocytes (KC) were y-irradiated (3000 rad, 137CS); however, because irradiated and unirradiated KC showed the same background proliferation and acted equally as stimulators of PBMC or T-cell proliferation, they were omitted after several experiments. After PMA treatment, HNK were washed five times to remove residual PMA, and allogeneic PBMC or T cells suspended in supplemented RPMI, including indomethacin (1 pg/ml), were added to the HNK at 5 X 10 4 cells/ dish. These were incubated for 72 h at 37°C in 5% CO 2 • Cocultures were pulsed for an additional 18 h with TdR (1 ,uCi/well) and then collected onto nitrocellulose filter paper using a Skatron cell harvester. Incorporated TdR was determined by liquid scintillation spectroscopy. All cultures were carried out in triplicate, and results were calculated as the mean cpm ± SD. In blocking experiments, MoAbs or appropriate isotype controls were added to the PBMC or T cells at· the indicated concentrations and remained in the cocultures throughout the incubation period.
RESULTS
To determine whether HNK express the B7 Ag, cultured HNK (second to fifth passages) were stained with three different anti-B7 antibodies and analyzed by FACS. Unstimulated HNK displayed only faint staining compared with the appropriate controls (Fig 1) . It should be noted, however, that this low constitutive B7 staining varied among HNK lines established from different donors (data not shown). Following PMA treatment, B7 staining was markedly upregulated (Fig 1) . Again, the intensity of this PMA-induced staining varied among different HNK lines (data not shown). It should also be noted that in five of a total of 36 experiments, no upregulation of B7 staining was detected, a phenomenon that may reflect the level of confluency ofHNK cultures prior to PMA stimulation (data not shown).
To determine the specificity of this PMA-induced B7 staining, anti-B7 MoAbs were pre-incubated with purified recombinant B7-Ig to block B7-specific epitopes. Such pre-incubation completely inhibited B7 staining on PMA-HNK (Fig 2) as well as on untreated HNK (data not shown). This inhibition was specific because pre-incubation of the anti-B7 MoAb with a human IgG did not significantly inhibit the MoAb binding to PMA-HNK (Fig 2) .
The next set of experiments was designed to gain insight into the mechanism by which PMA upregulates this molecule on HNK. To evaluate its dose dependency, HNK were stimulated with PMA concentrations ranging from 0.1 to 50 ng/ml. As shown in Fig 3, B7 staining rose in a linear fashion, with maximum induction at a concentration of25 ng/ml. In kinetic experiments, upregulation of B7 staining was first observed 16 h following PMA treatment and persisted for at least 48 II (Fig 4) Figure 3 . Dose dependence of PMA-induced upregulation of B7 staining on HNK. Second-to fifth-passage HNK were treated with PMA at the indicated concentrations (16 h, 37°C, 5% CO 2 ) and stained with MoAb BBl (IgM) and analyzed by FACS as described in Fig 1. HNK viability, as detennined by FACS using PI staining, exceeded 85% at all PMA concentrations tested. This graph depicts pooled data from three separate experiments and is expressed as percent mean fluorescence intensity (%MFI) ± SO of BBl (IgM) staining, the mean fluorescence intensity of untreated HNK being defined as 100%. log Fluorescence Figure 4 . Kinetics of PMA-induced upregulation of B7 staining on HNK. Third-passage HNK were PMA trea~ed (5 ng/ml) for the indicated time intervals. Thereafter, HNK were harvested, and BBl (IgM) staining was assessed by FACS, as described in Fig 1. HNK viability, as determined by PI staining, exceeded 90% at each time point.
protein synthesis because it was blocked by the specific PKC inhibitor GF 109203X [39] or the protein synthesis inhibitor cycloheximide, respectively (data not shown). Our first approach to elucidate the functional relevance ofpMAinduced upregulation of the B7 -like molecule was based on previous work in which we demonstrated that PMA-HNK would induce proliferation of allogeneic or autologous T cells via a mechanism that was mediated in part by PMA-induced ICAM-l [12] . We questioned whether a B7 -transduced signal played a role in this process. To address this issue, the capacity of anti-B7 MoAbs to block such proliferation of resting (i.e., CD2S-) PBMC and T cells was determined. As described previously [12] , PMA-HNK (but not untreated HNK) induced significant proliferative responses in allogeneic PBMC (Fig Sa,b) or in purified allogeneic T cells (Fig Sc,d) . The anti-B7 MoAb BBl reduced the capacity ofPMA-HNK to trigger PBMC or T-cell proliferation in a dose-dependent manner (Fig   Sb,d) . This inhibition was specific, with control MoAb of the same isotype having no effect (Fig Sb,d) . It is important to note that in this system, the anti-B7 MoAb did not abrogate PBMC or T-cell proliferation completely (Fig Sb,d) . This finding suggested tbat PMA induced on HNK the expression of a costimulatory molecule(s) other than B7, which also participates in T-cell activation. Our previous studies made the adhesion molecule ICAM-l an attractive candidate because the capacity ofpMA-HNK to activate T cells was also blocked in part by MoAbs directed against ICAM-1 [12] . To determine whether PMA-induced B7-like molecules and ICAM-1 deliver additive costimulatory signals, anti-B7 and anti-ICAM-1 MoAbs were used alone or in combination in the above-described blocking experiments. Indeed, the combination of anti-B7 and anti -ICAM-1 had additive effects, reducing T-cell proliferation to nearly background levels (Fig 6) . These data indicate that B7 and ICAM-1 expressed by PMA-HNK deliver additive accessory signals to T cells, ultimately leading to their activation and proliferation.
DISCUSSION
In the present study, we investigated the expression and function of the B7 Ag on KC, the major cell type within epidermis. Cultured KC expanded from normal human skin (HNK) display low constitutive staining with anti-B7 MoAb, paralleling recent findings by Fleming et al and Nickoloff et al. * In our experience, such constitutive B7 staining shows considerable variation, depending on the origin ofHNK lines and on their level of confluency at the time of staining. Following treatment of HNK with the phorbol ester PMA, a dose-dependent upregulation of B7 staining was observed . Such upregulation is not without precedent because treatment of tonsilar B cells with similar concentrations of PMA has also been shown to increase their B7 expression [23] . In kinetic experiments, upregulation ofB7 staining was first observed 16 h after PMA treatment and persisted for at least 48 h, again paralleling results obtained previously with B cells [18] . Furthermore, this effect was found to be PKC dependent and to require de novo protein synthesis on the basis of its sensitivity to the PKC inhibitor GF 109203X or cycloheximide, respectively. Does this PMA-induced staining identify bOlla fide B7 on HNK?
We consider it unlikely that staining was nonspecific because it was observed using three different MoAbs directed against B7; furthermore, isotype control MoAbs, even if used at tenfold excess, did not stain. That the MoAbs used by us identify a molecule closely related to B7 is further supported by competition experiments in which purified recombinant B7-Ig fusion proteins totally inhibited their binding to PMA-HNK. On the other hand, using sensitive polymerase chain reaction techniques, we have so far failed to detect significant amounts ofB7 mRNA in untreated or in PMA-HNK. Northern blot analysis. One explanation for these paradoxical results could be that PMA upregulates on HNK the expression of a surface molecule closely related but not identical to the B7 Ag. Although several lines of evidence suggest that BBI and B7 are highly related proteins encoded by the same gene [20, 27] , some differences exist between the two. For example, MoAbs directed against either BB 1 or B7 have been shown to differ in their staining patterns of several B-cell lines and neoplasms and to immunoprecipitate material of different molecular weights [18] . Furthermore, the gene encoding for B7 has very recently been located on chromosome 3 [43] , whereas BBl has been previously mapped to chromosome 12 [44] . On the basis of these findings, it could be possible that the molecule expressed by PMA-HNK is either the BB 1 glycoprotein itself, a splicing variant of B7 or yet another distinct but highly related molecule. Circumstantial support for the hypothesis that the B7 gene may code for divergent products comes from the observations that B7 is not very well conserved during evolution (i.e. , the homology of human and murine B7, particularly of their cytoplasmic regions, is less than 40%) [45] . To acknowledge both the ambiguity in this respect and the possibility that a distinct gene may code for these functionally and antige netically related molecules when expressed by KC, we have chosen to cite them as B7-like molecules.
Whatever the exact nature of this B7-like molecule is it was f?un? to. serve important costimulatory functions during T ~cell activation l11duced by PMA-HNK. Specifically, anti-B7 MoAbs were shown to re?uce th~ cap~city ofpMA-HNK to trigger proliferation of allogeneic, restl11g (I.e. , CD25-) PBMC and T cells. These MoAbs h~d previously been shown to inhibit the capacity of bona fide APC (I. e., activated B cells) to induce proliferation of allogeneic T cells [28, 38, 46] ; however, our studies are the first to demonstrate that it can block the capacity of an "alternative" APC (i.e., KC) to activate T cells. Although our inhibition studies using the MoAb BBl strongly suggest that interactions of B7-like molecules with CD28 are important for this proliferative response, we have yet to confirm this by blocking CD28 on T cells. Our findin g that the capacity of PMA-HNK to stimulate T-cell proliferation was never completely inhibited by anti-B7 MoAb suggested that in addition to B7, other costimulatory molecules mi ght be involved. Because our previous study had shown this proliferation to be partially ICAM-l dependent [12] , we questioned whether interaction of PMA-induced ICAM-l with its ligand LFA-l could provide this additional signal. Indeed, a combination of anti-B7 and anti-ICAM-l MoAbs inhibited T-cell proliferation to a much greater extent than either reagent alone, indicating that PMA-induced B7-like molecules and rCAM-l deliver additive activation signals to T cells. Cooperation of rCAM-l and B7 has also been described in other systems. For example, engagement of LFA-l enhances T-cell proliferation induced by anti-CD28/anti-CD2 MoAb [47) ; conversely, engagement of CD28 augments LFA-l/ rCAM-l-mediated T-cell adhesion [30, 48] .
Our findings do not preclude, however, that in addition to ICAM-l and B7-like molecules, other costimulatory surface recep-tors contribute to T-cell proliferation induced by PMA-HNK. Do signals delivered by residual PMA carried over by HNK after washing add to this proliferative response? This question is important in light of previous findings demonstrating proliferation of purified T cells after effective ligation of CD28 plus PMA treatment [17, 49] . It should be noted, however, that these studies used PMA concentrations th at by far exceeded those left on PMA-HNK after washing [12] . On the basis of our previous work, w e are confident that T-cell proliferation is not solely due to PMA carryover [12] ; however, we cannot exclude the fact that trace amounts of membrane-bound PMA, in addition to B7-like molecules and ICAM-1, contribute to T-cell activation induced by PMA-HNK.
In summary, we have demonstrated that cultured HNK activated ill lIitro by the phorbol ester PMA upregulate th eir expression of a molecule closely re lated to the B7 Ag. These B7 -like molecules and ICAM-1 , expressed simultaneously by PMA-HNK, synergize in inducin g proliferation of resting allogeneic T cells. On the basis of these findings, we hypothesize that in inflammatory dermatoses, "activated" EC and dermal cells also co-express "B7" and ICAM-l. In fact, we have observed B7 and ICAM-1 staining in lesional skin of patients with psoriasis, allergic contact dermatitis, and cutaneous T-cell lymphoma (manuscript in preparation). It is therefore not unreaso nable to speculate that in T-cell-mediated skin diseases, B7-like molecules and ICAM-1 on "activated" EC and dermal cells cooperate to promote adhesion, activation, and cytotoxicity of CD28+/LFA-1+ T lymphocytes. 
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